Live Chat ×
Skip to main content

Best Practices for Identification of Carbapenem Resistant Pseudomonas aeruginosa An ASM-APHL- CDC Sponsored Training Webinar

Description

Carbapenem Resistant Pseudomonas aeruginosa (CRPA) refers to carbapenem-resistant and carbapenemase-producing Pseudomonas aeruginosa. In 2010, carbapenemases known as metallo-β-lactamases (MBL) were first detected in the U.S.: New Delhi MBL (NDM) and Verona integron-encoded MBL (VIM). Currently, the most common type of carbapenemase seen in P. aeruginosa worldwide is VIM. The genes encoding carbapenemases are often located on plasmids that are easily spread between organisms. This webinar will discuss best practices for the laboratory identification of CRPA and the importance of communication between clinical labs and public health/labs about their test methods and results.

Objectives:

  1. Describe the growing threat of Carbapenem Resistant Pseudomonas aeruginosa (CRPA) and the role of the clinical laboratory in identifying and containing its spread.
  2. Review available test methods and best practices for CRPA identification and susceptibility testing.
  3. Identify CRPA testing services offered through the AR Laboratory Network and explain how they can support health care facilities.

Faculty:
  • Moderator
    • William A. Glover II, PhD, D(ABMM), MT(ASCP)
      Assistant Director, Infectious Diseases
      North Carolina Department of Health and Human Services
  • Speaker
    • Patricia J. Simner, MSc, PhD, D(ABMM)
      Associate Professor of Pathology
      Johns Hopkins Medicine 

Contributors

  • Patricia J. Simner, PhD, D(ABMM)

    Assistant Professor of Pathology and Medicine
    Director of Bacteriology and Parasitology, Division of Medical Microbiology
    Johns Hopkins Medical Institute

July 9, 2019
Tue 2:00 PM EDT

Duration 1H 0M

Register Already Registered?